PIB TrackerA cancer drug that stays switched off until it reaches a cancer cell
RK-251, developed at IASST Guwahati with IIT-Guwahati, is activated by the high reactive oxygen species inside tumour cells — the property that makes cancer cells dangerous becomes the trigger.
What happened
- RK-251 is a 'smart' anticancer candidate that activates only inside cancer cells.
- It was developed at IASST Guwahati with IIT-Guwahati.
- High reactive oxygen species (ROS) inside tumour cells trigger activation.
- Activation releases the anticancer compound NBDHEX.
- Preclinical activity was shown against triple-negative breast cancer cells.
For Prelims
- RK-251: a ROS-activated anticancer candidate — inactive in circulation, switched on inside the tumour cell.
- Reactive oxygen species (ROS): reactive oxygen-containing molecules produced at elevated levels by cancer cells.
- NBDHEX: the anticancer compound released on activation; it blocks proteins cancer cells use to survive and resist treatment.
- IASST: the Institute of Advanced Study in Science and Technology, Guwahati — an autonomous institute of the DST.
- Triple-negative breast cancer: a subtype lacking the three common receptor targets, hence hard to treat.
- Zebrafish (Danio rerio): a standard vertebrate model for early toxicity screening.
- Published in: the ACS Journal of Medicinal Chemistry.
- Stage: preclinical — not yet tested in patients.
For UPSC: A clean illustration of targeted therapy and of Indian institutional research collaboration. Use it for biotechnology in health, the DST's autonomous institute network and the translation gap between publication and patient.
What it is NOT: This is a preclinical candidate, not an approved drug — cell-line and zebrafish results are the beginning of a development path that most molecules do not complete.
For Mains
Syllabus: GS3.13 · GS3.11 · Linkage L2
Anchor
Targeted therapy works by finding a condition unique to the diseased cell and making the drug depend on it — here, the tumour's own oxidative stress becomes the switch.
Substantiation (data)
RK-251 releases NBDHEX on encountering elevated ROS, showing strong preclinical activity against triple-negative breast cancer cells with much less effect on healthy cells.
Exemplification
IASST Guwahati working with IIT-Guwahati — a DST autonomous institute in the Northeast publishing in the ACS Journal of Medicinal Chemistry.
Problematisation
Preclinical selectivity rarely survives to the clinic; ROS levels vary across tumour types and within a single tumour, so the trigger may be uneven in practice.
Way-forward
Fund the translational stage — toxicology, formulation and early-phase trials — which is where Indian candidate molecules most often stall.
Position
India publishes strong early-stage pharmacology; the deficit is in carrying molecules through development, not in discovering them.
Deploys into: Biotechnology + S&T in everyday life (GS3.13, GS3.11) · targeted cancer therapy, DST autonomous institutes and the translational research gap.
Ministry of Science & Technology · 2026-08-19 · PRID 2301318 · PIB source ↗